LYEL
Lyell Immunopharma, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-49/100
Last price
8.61
▼ 0.46 (5.07%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
9.16
Prev close
9.07
Day high
9.07
Day low
8.59
Volume
125.04K
Market cap
$210.99M
P/E (TTM)
—
52W range
8.59 – 45.00
Day trading desk
Gap from prior close
+0.97%
Prior close 9.07
VWAP
8.78
-1.88% from price
Relative volume
0.78×
Normal
Session range
6.70%
8.59 – 9.16
Position in range
4%
Near session low
ATR (14D)
0.51
5.91% of price
Prior day high
9.31
PDH
Prior day low
8.66
PDL
Bid / ask spread
—
Quote not published
Session volume
114.85K
Avg 146.48K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-10.59%
-12.5%
1M
-40.08%
-41.2%
3M
-44.09%
-48.6%
6M
-60.47%
-78.7%
YTD
-72.03%
-86.3%
1Y
-51.49%
-67.9%
3Y
-70.71%
-153.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on LYEL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
9.14M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 10, 26 | SHOOK DAVID M.D. Officer |
SELL | 500 | $6.35K | Direct |
| Aug 21, 26 | SEELY LYNN Chief Executive Officer |
SELL | 9.59K | $149.01K | Direct |
| Aug 21, 26 | HILL STEPHEN J Chief Operating Officer |
SELL | 989 | $15.37K | Direct |
| Aug 21, 26 | LEE GARY K Officer |
SELL | 1.46K | $22.64K | Direct |
| Aug 10, 26 | SEELY LYNN Chief Executive Officer |
SELL | 390 | $5.59K | Direct |
| Aug 10, 26 | HILL STEPHEN J Chief Operating Officer |
SELL | 89 | $1.28K | Direct |
| Aug 10, 26 | LEE GARY K Officer |
SELL | 131 | $1.88K | Direct |
| Aug 10, 26 | BULIS VERONICA SANCHEZ Officer |
SELL | 621 | $8.90K | Direct |
| Jul 17, 26 | INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD Beneficial Owner of more than 10% of a Class of Security |
SELL | 10 | $137 | Direct |
| Jul 16, 26 | INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD Beneficial Owner of more than 10% of a Class of Security |
SELL | 10 | $137 | Direct |
| Jun 10, 26 | SHOOK DAVID M.D. Officer |
SELL | 1.98K | $24.99K | Direct |
| May 11, 26 | SEELY LYNN Chief Executive Officer |
SELL | 388 | $7.34K | Direct |
| May 11, 26 | HILL STEPHEN J Chief Operating Officer |
SELL | 89 | $1.68K | Direct |
| May 11, 26 | LEE GARY K Officer |
SELL | 130 | $2.46K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ARCH VENTURE FUND XIII, L..P |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
ARCH VENTURE PARTNERS IX,L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
BRAWLEY OTIS W |
Director | 35.64K | Purchase |
INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD |
Beneficial Owner of more than 10% of a Class of Security | 2.86M | Sale |
KLAUSNER RICHARD |
Director | — | Purchase |
LANG MATTHEW |
Officer | 162.50K | Stock Award(Grant) |
NEWTON CHARLES W. |
Chief Financial Officer | 25.31K | Sale |
RAMACHANDRA SUMANT |
Director | — | Purchase |
SEELY LYNN |
Chief Executive Officer | 63.90K | Sale |
SHOOK DAVID M.D. |
Officer | 20.42K | Sale |
Fundamentals
Market cap$210.99M
Enterprise value$53.49M
Revenue (TTM)$27.00K
Gross profit$27.00K
EBITDA$-180.94M
Net income$-248.48M
EPS (TTM)$-12.86
Free cash flow$-72.81M
Total cash$204.10M
Total debt$46.60M
Book value / share$9.99
Shares outstanding24.51M
Float12.13M
Short % of float5.66%
Dividend yield0.00%
Beta (5Y)-0.03
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.36
PEG ratio—
Price / sales—
Price / book0.86
EV / revenue1,980.94
EV / EBITDA-0.30
Gross margin100.00%
Operating margin-1183425.00%
Profit margin0.00%
Return on equity-93.28%
Return on assets-34.18%
Debt / equity19.93
Current ratio5.36
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $36.00K | $61.00K | $130.00K | $84.68M | -41.0% |
| Operating revenue | $36.00K | $61.00K | $130.00K | $84.68M | -41.0% |
| Research & development | $158.68M | $171.60M | $182.94M | $159.19M | -7.5% |
| Selling, general & admin | $45.13M | $52.04M | $66.98M | $117.31M | -13.3% |
| Total operating expense | $201.66M | $220.34M | $247.14M | $271.74M | -8.5% |
| Operating income | -$201.63M | -$220.27M | -$247.01M | -$187.06M | +8.5% |
| Net interest income | $13.08M | $24.07M | $23.45M | $7.05M | -45.7% |
| Pre-tax income | -$274.45M | -$342.99M | -$234.63M | -$183.12M | +20.0% |
| Net income | -$274.45M | -$342.99M | -$234.63M | -$183.12M | +20.0% |
| Net income to common | -$274.45M | -$342.99M | -$234.63M | -$183.12M | +20.0% |
| Basic EPS | -12.91 | -23.26 | -18.70 | -14.80 | +44.5% |
| Diluted EPS | -12.91 | -23.26 | -18.70 | -14.80 | +44.5% |
| EBIT | -$201.63M | -$220.27M | -$247.01M | -$187.06M | +8.5% |
| EBITDA | -$190.09M | -$200.64M | -$226.76M | -$169.04M | +5.3% |
| Basic shares | 21.25M | 14.74M | 12.55M | 12.35M | +44.1% |
| Diluted shares | 21.25M | 14.74M | 12.55M | 12.35M | +44.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $60.18M | $105.60M | $145.65M | $123.55M | -43.0% |
| Cash & short-term investments | $247.22M | $370.53M | $546.22M | $640.15M | -33.3% |
| Total current assets | $260.94M | $379.59M | $554.69M | $651.29M | -31.3% |
| Property, plant & equipment | $53.64M | $72.94M | $142.32M | $166.26M | -26.5% |
| Total assets | $340.05M | $490.86M | $750.03M | $937.56M | -30.7% |
| Total current liabilities | $49.41M | $53.79M | $34.52M | $37.03M | -8.1% |
| Total debt | $50.99M | $58.97M | $63.17M | $67.70M | -13.5% |
| Total liabilities | $91.85M | $108.03M | $95.08M | $104.31M | -15.0% |
| Retained earnings | -$1.62B | -$1.35B | -$1.00B | -$767.48M | -20.4% |
| Shareholder equity | $248.20M | $382.82M | $654.95M | $833.25M | -35.2% |
| Working capital | $211.53M | $325.81M | $520.17M | $614.27M | -35.1% |
| Net tangible assets | $248.20M | $382.82M | $654.95M | $833.25M | -35.2% |
| Shares issued | 21.25M | 14.74M | 12.70M | 12.48M | +44.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$274.45M | -$342.99M | -$234.63M | -$183.12M | — | +20.0% |
| Depreciation & amortisation | $11.54M | $19.63M | $20.25M | $18.02M | — | -41.2% |
| Stock-based compensation | $41.83M | $33.14M | $47.08M | $81.92M | — | +26.2% |
| Change in working capital | -$9.89M | -$3.12M | $3.42M | -$82.02M | — | -217.1% |
| Operating cash flow | -$150.02M | -$162.39M | -$163.69M | -$169.56M | — | +7.6% |
| Capital expenditure | -$780.00K | -$464.00K | -$2.69M | -$24.28M | — | -68.1% |
| Investing cash flow | $54.10M | $122.42M | $184.05M | -$11.54M | — | -55.8% |
| Share buybacks | — | — | — | $0 | $0 | — |
| Financing cash flow | $50.41M | $1.33M | $1.74M | $10.63M | — | +3,701.4% |
| Free cash flow | -$150.80M | -$162.86M | -$166.38M | -$193.83M | — | +7.4% |
| End cash position | $61.77M | $107.29M | $145.93M | $123.83M | — | -42.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $4.00K | $2.00K | $6.00K | $15.00K | $8.00K | +100.0% |
| Operating revenue | $4.00K | $2.00K | $6.00K | $15.00K | $8.00K | +100.0% |
| Research & development | $39.52M | $36.60M | $52.20M | $28.17M | $34.86M | +8.0% |
| Selling, general & admin | $9.58M | $9.55M | $10.62M | $10.69M | $9.79M | +0.2% |
| Total operating expense | $47.34M | $44.26M | $61.32M | $37.27M | $45.70M | +7.0% |
| Operating income | -$47.34M | -$44.26M | -$61.31M | -$37.25M | -$45.70M | -6.9% |
| Net interest income | $2.18M | $2.19M | $2.68M | $3.27M | $3.28M | -0.5% |
| Pre-tax income | -$44.76M | -$24.15M | -$140.72M | -$38.85M | -$42.68M | -85.3% |
| Net income | -$44.76M | -$24.15M | -$140.72M | -$38.85M | -$42.68M | -85.3% |
| Net income to common | -$44.76M | -$24.15M | -$140.72M | -$38.85M | -$42.68M | -85.3% |
| Basic EPS | -1.92 | -1.10 | -6.62 | -2.13 | -2.89 | -74.5% |
| Diluted EPS | -1.92 | -1.10 | -6.62 | -2.13 | -2.89 | -74.5% |
| EBIT | -$47.34M | -$44.26M | -$61.31M | -$37.25M | -$45.70M | -6.9% |
| EBITDA | -$45.12M | -$41.93M | -$58.91M | -$34.69M | -$42.56M | -7.6% |
| Basic shares | 23.36M | 21.88M | 21.25M | 18.27M | 14.79M | +6.8% |
| Diluted shares | 23.36M | 21.88M | 21.25M | 18.27M | 14.79M | +6.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $72.98M | $90.77M | $60.18M | $123.58M | $98.80M | -19.6% |
| Cash & short-term investments | $204.10M | $254.02M | $247.22M | $319.62M | $276.79M | -19.7% |
| Total current assets | $213.54M | $267.30M | $260.94M | $328.20M | $282.21M | -20.1% |
| Property, plant & equipment | $47.29M | $50.55M | $53.64M | $56.63M | $60.07M | -6.4% |
| Total assets | $311.15M | $350.63M | $340.05M | $407.96M | $385.45M | -11.3% |
| Total current liabilities | $39.87M | $36.95M | $49.41M | $31.88M | $36.90M | +7.9% |
| Total debt | $36.93M | $39.49M | $50.99M | $44.28M | $46.60M | -6.5% |
| Total liabilities | $77.34M | $76.96M | $91.85M | $78.84M | $86.53M | +0.5% |
| Retained earnings | -$1.69B | -$1.64B | -$1.62B | -$1.48B | -$1.44B | -2.7% |
| Shareholder equity | $233.81M | $273.67M | $248.20M | $329.12M | $298.92M | -14.6% |
| Working capital | $173.67M | $230.36M | $211.53M | $296.32M | $245.31M | -24.6% |
| Net tangible assets | $233.81M | $273.67M | $248.20M | $329.12M | $298.92M | -14.6% |
| Shares issued | 23.40M | 23.33M | 21.25M | 19.29M | 14.83M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$44.76M | -$24.15M | -$140.72M | -$38.85M | -$42.68M | -85.3% |
| Depreciation & amortisation | $2.22M | $2.33M | $2.40M | $2.57M | $3.13M | -4.7% |
| Stock-based compensation | $4.53M | $4.29M | $25.57M | $5.23M | $5.00M | +5.5% |
| Change in working capital | $6.39M | -$1.08M | $672.00K | -$136.00K | -$876.00K | +689.4% |
| Operating cash flow | -$33.92M | -$38.51M | -$32.25M | -$28.58M | -$34.46M | +11.9% |
| Capital expenditure | -$256.00K | -$89.00K | -$304.00K | -$62.00K | -$168.00K | -187.6% |
| Investing cash flow | $15.62M | $17.38M | -$31.36M | $3.35M | $12.65M | -10.1% |
| Financing cash flow | $522.00K | $51.72M | $222.00K | $50.00M | $183.00K | -99.0% |
| Free cash flow | -$34.18M | -$38.60M | -$32.55M | -$28.64M | -$34.63M | +11.5% |
| End cash position | $74.57M | $92.36M | $61.77M | $125.16M | $100.39M | -19.3% |
Options analytics
Put / call volume
5.42
Put-heavy session
Put / call open interest
1.61
Positioning, not flow
Max pain
14.00
+62.6% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
190
Contracts, this expiry
Put volume
1.03K
Contracts, this expiry
Heaviest call OI
12.00
31 contracts
Heaviest put OI
14.00
36 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.79 | -1.74 | +2.9% |
| Mar 2026 | -2.36 | -1.10 | +53.5% |
| Dec 2025 | -2.23 | -7.68 | -244.1% |
| Sep 2025 | -2.64 | -2.13 | +19.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.88 | 1 | $3.29K | -78.1% |
| Next quarter | -1.61 | 1 | $2.43K | -59.5% |
| Current year | -6.92 | 1 | $11.88K | -67.0% |
| Next year | -6.32 | 1 | $9.88K | -16.8% |
Analyst targets & ownership
Mean target$37.88
High target$49.00
Low target$12.00
Implied upside339.90%
Analyst count8
ConsensusBUY
Strong buy / Buy2 / 5
Hold0
Sell / Strong sell0 / 1
Held by insiders37.31%
Held by institutions54.22%
Institutions holding124
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
9.60
-10.32% from price
SMA 20
10.50
-17.98% from price
SMA 50
12.77
-32.59% from price
SMA 100
13.51
-36.29% from price
SMA 200
18.74
-54.06% from price
EMA 12
9.83
-12.38% from price
EMA 26
10.99
-21.65% from price
EMA 50
12.19
-29.35% from price
RSI (14)
21.1
Oversold
MACD (12,26,9)
-1.16
Hist -0.09
ATR (14)
0.51
5.91% of price
Realised vol 30D
45.0%
Annualised
Bollinger upper
12.66
20, 2σ
Bollinger lower
8.34
20, 2σ
50 / 200 cross
Death
12.77 vs 18.74
Trend bias
Below 200
-54.06%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.64
More volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
45.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-77.7%
Peak to trough
Max drawdown 5Y
-97.4%
Peak to trough
ATR 14
0.51
5.91% of price
Beta (reported)
-0.03
5Y monthly, from filing
Short interest
Shares short
1.19M
Prior 1.15M
Change vs prior
+3.1%
Shorts adding
% of float
5.66%
Normal
% of shares out
4.85%
Against total outstanding
Days to cover
10.3
Crowded exit
Float
12.13M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 11, 26 | Needham | MAINTAINED | Buy | Buy |
| Aug 6, 26 | Stifel | INITIATED | — | Buy |
| Jul 22, 26 | B. Riley Securities | INITIATED | — | Buy |
| Jun 15, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Jun 15, 26 | Needham | MAINTAINED | Buy | Buy |
| Jun 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 8, 26 | Needham | MAINTAINED | Buy | Buy |
| Jun 3, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 7, 26 | Needham | MAINTAINED | Buy | Buy |
| Apr 10, 26 | Needham | INITIATED | — | Buy |
| Mar 9, 26 | Citizens | INITIATED | — | Market Outperform |
| Dec 9, 25 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:20
Split dateJun 2, 2025
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-10
Corporate Changes & Voting Matters
8-K · 2026-08-06
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-07-17
Offering Registrations
S-3 · 2026-07-13
Corporate Changes & Voting Matters
8-K · 2026-06-15
Corporate Changes & Voting Matters
8-K · 2026-05-06
Proxy Statements
DEFA14A · 2026-04-24
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-04-13
Headlines
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
GlobeNewswire · 23d ago
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
GlobeNewswire · 26d ago
Lyell Immunopharma: Q2 Earnings Snapshot
Associated Press · 61d ago
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
GlobeNewswire · 61d ago
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
The Fly · 62d ago
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
24/7 Wall St. · 62d ago
Stifel Initiates Lyell Immunopharma at Buy With $36 Price Target
MT Newswires · 62d ago
B. Riley Initiates Lyell Immunopharma at Buy With $44 Price Target
MT Newswires · 77d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.